Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir Pharmaceuticals, Inc. has announced new in vitro findings demonstrating that their lead candidate, Telomir-1, now inhibits the KDM5 histone demethylase family. This adds to its previously reported activity against KDM2 and KDM6 families, highlighting a broad epigenetic therapy potential unseen in other treatments. These results position Telomir-1 as a potential first-in-class therapy addressing cancer and aging by resetting key epigenetic controls.

Histone demethylases like KDM5, when overactive, can silence critical tumor suppressor genes, enabling cancer progression. Telomir-1's inhibition of these enzymes suggests a new therapeutic path, tackling both histone and DNA methylation alterations, potentially restoring cellular defenses. The therapy's dual action may reverse silencing patterns linked to disease and aging.

Telomir is advancing IND-enabling studies for Telomir-1, continuing preclinical evaluations in cancers and aging models. These studies aim to support future clinical trial submissions.